Ranolazine

Category: pharmacological

Aliases: Ranexa

Pharmacological Mechanism

Late sodium current (INa-late) inhibitor in cardiomyocytes — reduces Ca²⁺ overload and improves diastolic function. Anti-anginal without significant heart-rate or BP effects. CYP3A4 + P-gp substrate; QT prolongation modest. Mild HbA1c reduction signal.

Half-Life (t½)

PO: 7h

Dosing Guidelines

• PO: Typical 1000mg (Range: 500 - 1000 mg)

Target Organ Systems

• cardiovascular
• digestive